Services / Drug Discovery & Development Services / Pathway Profiling / pathELECT
Find a Product
Services

pathELECT℠ Personalized Screening & Profiling

pathELECT provides you access to a growing menu of novel biosensor assays that monitor multiple stages of cell signaling to determine whether a target protein degrades, translocates or is secreted. Screen or profile your compounds against one of our functional whole cell pathway signaling assays. pathELECT is a simple and cost-effective alternative to in-house profiling and screening and is ideal for any size compound collection, providing you a flexible solution for hit identification and ongoing lead optimization & SAR.

Request a Quote

Panel Features & Benefits

  • Single functional readout – applicable to different kinase receptors and families
  • Stable cell lines - increased reliability and reproducibility
  • All cell lines functionally validated to ensure high-quality results every time
  • High specificity – tagged protein eliminates background from endogenous proteins
  • High quality reproducible data – superior assay windows & robust performance (Z' > 0.6)
 How it Works

Screen for Activators or Inhibitors of PI3-K/AKT Signalling



PathHunter® assays are able to measure FOXO translocation in response to PI3 or AKT inhibition.

pathELECT Assay Panel

Listed below are the assays currently available for screening and profiling.

 
Target Gene ▲Common NameFamilyAccession No.
BCL2-BAXBCL2 B-cell CLL/lymphoma 2 (Bcl-2)BCL2NM_000633
BCL2-BIMBCL2 B-cell CLL/lymphoma 2 (Bcl-2)BCL2NM_000633
BCL2L1-BAXBCL2-like 1 (Bcl-xL)BCL2NM_138578.1
BCL2L1-BIMBCL2-like 1 (Bcl-xL)BCL2NM_138578.1
CDC25ACell division cycle 25 homolog A (CDC25A)Cell Cycle ProteinNM_001789.2
FOXO3forkhead box O3 (forkhead box O3)PathwayNM_001455
IκBnuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA)PathwayNM_020529
Keap1-NRF2nuclear factor (erythroid-derived 2)-like 2 (NFE2L2)Transcription FactorNM_006164
MCL1-BIMMyeloid cell leukemia sequence 1 (Mcl-1)BCL2NM_021960
NIKmitogen-activated protein kinase kinase kinase 14 (NIK)STENP_003945.2
NPR1Natriuretic peptide receptor A (NPR1)Guanylate Cyclase ANM_000906.3
P53P53 (P53)Nuclear TranslocationNM_000546.2
RANK-IκBTumor necrosis factor receptor superfamily, member 11a (TNFRSF11A)Tumor Necrosis Factor Receptor SuperfamilyNM_003839.3
RELA-IκBv-rel reticuloendotheliosis viral oncogene homolog A (avian) (RELA)Transcription factorNM_021975
SREBP2Sterol regulatory element binding transcription factor 2 (SREBF2)Transcription FactorNM_004599.2
TORC1CREB regulated transcription coactivator 1 (CRTC1)Transcription factorNM_015321.1
TORC2CREB regulated transcription coactivator 2 (CRTC2)Transcription factorNM_181715
XBP1X-box binding protein 1 (XBP1)Transcription factorBC012841
β-CateninCatenin (cadherin-associated protein), beta 1 (CTNNB1)Wnt-Frizzled signallingNM_001904

Data Analysis & Interpretation 

Definitions

Percent Activity/Inhibition

The results for single concentration (primary screen) for tested compound(s) are reported in your study report and spreadsheets as '% Activity' or '% Inhibition' and are calculated in the following manner:
 

% Activity
(Agonist Mode) =
100% x
 [
Mean RLU (test sample)- Mean RLU(vehicle control)
Mean MAX RLU (control ligand)- Mean RLU (vehicle control)
 ]
 

test sample = client supplied compound
vehicle control = DMSO (0% activity)
control ligand = control compound (100% activity)
 

% Inhibition
(Antagonist mode) =
100% x
 [ 1- 
Mean RLU (test sample)- Mean RLU(vehicle control)
Mean MAX RLU (control ligand)- Mean RLU (vehicle control)
 ]
 

test sample = client supplied compound
vehicle control = DMSO (0% activity)
EC80 control = control compound (80% activity) 
 

Dose Response Curve (EC50/IC50)

The results for 10-point dose response curve compound/target interactions are reported in the study report and spreadsheets as EC50/IC50, which are values derived using the Hill equation:

hill equation